Idelalisib With Rituximab Boosts Survival in Relapsed CLL Medscape In a phase 3 trial, known as Study 116, the investigational agent idelalisib (under development by Gilead), when added to rituximab (Rituxan), improved outcomes in patients with relapsed CLL. "Idelalisib is a targeted, highly selective, orally ... Idelalisib plus rituximab extended survival in previously treated CLL Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL Gilead's Pipeline Encourages |
